MedTrace Logo

Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma

NCT07752394 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-08-07

No results posted yet for this study

Summary

This is a prospective, single-arm, phase II clinical study aimed to evaluate the efficacy and safety of penpulimab combined with chemotherapy in the treatment of locally advanced hypopharyngeal carcinoma.

Conditions

  • Head & Neck Cancer

Interventions

DRUG

Finotonlimab

Finotonlimab was administered by intravenous infusion at a dose of 200 mg,d1, Q3W,for 2-4 cycles Other Name:

DRUG

Nab-paclitaxel

treatment Regimen:Nab-paclitaxel was administered by intravenous infusion at a dose of 260mg/m² ,d1, Q3W,for 2-4 cycles

DRUG

carboplatin

treatment Regimen: Carboplatin dosage was calculated using the Calvert formula (dose = target AUC × \[GFR + 25\]), d1,IV,Q3W,for 2-4 cycles

Sponsors & Collaborators

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • DaQing Zhao · Tangdu Hospital, Air Force Medical University (AFMU), Xi'an, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-23
Primary Completion
2031-08-23
Completion
2031-08-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07752394 on ClinicalTrials.gov